Traduction de «anticoagulant therapy safely prevented stroke » (Français → Néerlandais) :

Dunn A. Oral anticoagulant therapy safely prevented stroke in older patients with atrial fibrilllation. Evid Based Med 2009; 14:140.
Bespreking van: van Walraven C, Hart RG, Conolly S et al. Effect of age on stroke prevention therapy in patients with atrial fibrillation: the Atrial Fibrillation Investigators.

Powers: Oral anticoagulant therapy for the prevention of stroke (editorial) New Engl.
345, 1493-1495 (2001) J.P. Mohr et al.: A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke.

W.J. Powers: : Oral anticoagulant therapy for the prevention of stroke (editorial).
W.J. Powers (editorial): : Oral anticoagulant therapy for the prevention of stroke.

Aguilar MI, Hart R. Oral anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks.
Hart RG, Pearce LA, Aguilar MI. Meta-analysis: anti-thrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation.

randomized trials.1 Effective strategies for the secondary prevention of stroke include treatment of hypertension and hyperlipidemia, antithrombotic therapy for patients with atrial fibrillation, and antiplatelet therapy (Evidence level 1). 1 Statins are effective in the prevention of stroke, although evidence remains limited to heart disease patients (Evidence level 1). 2, 3
treatment of hypertension and hyperlipidemia, antithrombotic therapy for patients with atrial fibrillation, and antiplatelet therapy (Evidence level 1).1 Statins are effective in the prevention of stroke, although evidence remains limited to heart disease patients (Evidence level 1).2, 3

Ces recommandations parues dans les Folia d’août 2000 reposent entre autres sur l’étude SPIRIT («Stroke Prevention in Reversible Ischemia Trial»), une étude randomisée contrôlée, dans laquelle un anticoagulant oral (avec un INR recherché entre 3,0 et 4,5) et l’acide acétylsalicylique (30 mg p.j. ou plus) ont été comparés en prévention secondaire d’un AVC chez 1.316 patients sans cardiopathie emboligène.
De aanbevelingen in de Folia van augustus 2000 berustten vooral op de SPIRITstudie (“Stroke Prevention in Reversible Ischemia Trials”), een gerandomiseerde, gecontroleerde studie, waarbij in de secundaire preventie van cerebrovasculair accident een oraal anticoagulans (streefwaarde voor de INR tussen 3,0 en 4,5) en acetylsalicylzuur (30 mg p.d. of meer) werden vergeleken bij 1.316 patiënten zonder emboligene cardiopathie.

Ces recommandations parues dans les Folia d’ août 2000 reposent entre autres sur l’étude SPIRIT (" Stroke Prevention in Reversible Ischemia Trial "), une étude randomisée contrôlée, dans laquelle un anticoagulant oral (avec un INR recherché entre 3,0 et 4,5) et l’acide acétylsalicylique (30 mg p.j. ou plus) ont été comparés en prévention secondaire d’un AVC chez 1.316 patients sans cardiopathie emboligène.
De aanbevelingen in de Folia van augustus 2000 berustten vooral op de SPIRIT-studie (" Stroke Prevention in Reversible Ischemia Trials "), een gerandomiseerde, gecontroleerde studie, waarbij in de secundaire preventie van cerebrovasculair accident een oraal anticoagulans (streefwaarde voor de INR tussen 3,0 en 4,5) en acetylsalicylzuur (30 mg p.d. of meer) werden vergeleken bij 1.316 patiënten zonder emboligene cardiopathie.

Search Date February 2009. [http ...]
Aguilar MI, Hart R. Antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks.

For primary prevention of stroke, adequate blood pressure reduction, and treatment of hyperlipidemia, use of antithrombotic therapy in patients with atrial fibrillation and of antiplatelet therapy in patients with myocardial infarction are effective and supported by evidence from several
For primary prevention of stroke, adequate blood pressure reduction, and treatment of hyperlipidemia, use of antithrombotic therapy in patients with atrial fibrillation and of antiplatelet therapy in patients with myocardial infarction are effective and supported by evidence from several randomized trials.1 Effective strategies for the secondary prevention of stroke include

Hart RG, Pearce LA et Aguilar MI: Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation.
Hart RG, Pearce LA en Aguilar MI: Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation.